HIV-Specific Effector Activity In Patients In Primary HIV Infection

The Journal of Infectious DiseasesAlter, G, A Merchant, CM Tsoukas, D Rouleau, R LeBlanc, P Côté, J-G Baril, R Thomas, VK Nguyen, R Sékaly and J-P Routy, and NF Bernard. HIV-Specific Effector Activity In Patients In Primary HIV Infection. Journal of Infectious Diseases 2002; 185: 755-765.

Discount Oakley sunglasses
Inexpensive ray ban sunglasses
The interferon-γ ELISPOT assay was used to assess and compare the magnitude and breadth of human immunodeficiency virus (HIV)-specific CD8 T cell responses in treatment-naive subjects during the first year of HIV primary infection and during the chronic phase of infection. Twenty-five subjects tested within a year of exposure to HIV resulting in seroconversion and 20 subjects with chronic infection were screened for HIV peptide-specific activity by stimulating peripheral blood mononuclear cells with a panel of 5–21 HLA class I-restricted HIV peptides (mean, 11.2 ± 3.5 HIV peptides). There was a significant correlation between the magnitude and breadth of HIV-specific effector responses and time elapsed from exposure (r = 0.63 for magnitude vs. time and r = 0.64 for breadth vs. time; P < .02, paired t test). Maximal breadth of the HIV gene product reactivity was achieved within 2 months of exposure for Nef-specific responses and by 4 months of exposure for responses directed to Env, Gag, and reverse transcriptase.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.